查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
小鼠模型技術的全球市場:各技術 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)
市場調查報告書
商品編碼
1140625

小鼠模型技術的全球市場:各技術 - 產業分析，規模，佔有率，成長，趨勢，預測(2022年～2031年)

Mice Model Technologies Market (Technology: CRISPR Knockout; CRISPR Knockin; Random Insertions; Large, Targeted Insertions; ES Cell Modification; and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日期: | 出版商: Transparency Market Research | 英文 233 Pages | 商品交期: 2-10個工作天內

價格

本報告提供全球小鼠模型技術市場相關調查分析，提供市場趨勢，市場區隔分析，地區分析，企業簡介等資訊。

目錄

第1章 序文

第2章 前提與調查手法

第3章 摘要整理:全球小鼠模型技術市場

第4章 市場概要

  • 簡介
    • 市場區隔定義
  • 概要
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 全球小鼠模型技術市場分析與預測(2017年～2031年)
    • 市場收益預測

第5章 主要考察

  • 全球遺傳基因改變小鼠模型概要
  • 法規情景:各地區，世界
  • 技術的進步
  • 主要的產業活動(合併，收購，夥伴關係，聯盟等)
  • 產業的COVID-19疫情的影響(價值鏈和短期·中期·長期性影響)

第6章 全球小鼠模型科技市場分析與預測:各技術

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各技術(2017年～2031年)
    • CRISPR敲除
    • CRISPR敲門
    • 隨機插入
    • 大而有針對性的插入
    • ES細胞修飾（同源重組）
    • 其他
  • 市場魅力:各技術

第7章 全球小鼠模型科技市場分析與預測:各終端用戶

  • 簡介和定義
  • 主要調查結果/發展
  • 市場金額的預測:各終端用戶(2017年～2031年)
    • 製藥企業
    • 生物科技企業
    • 學術·研究設施
    • 開發·受託製造廠商
  • 市場魅力:各終端用戶

第8章 全球小鼠模型科技市場分析與預測:各地區

  • 主要調查結果
  • 市場金額的預測:各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力:各國各地區

第9章 北美的小鼠模型技術市場分析與預測

  • 簡介
    • 主要調查結果
  • 市場金額的預測:各技術(2017年～2031年)
  • 市場金額的預測:各終端用戶(2017年～2031年)
  • 市場金額的預測:各技術(2017年～2031年)
  • 市場金額的預測:各國(2017年～2031年)
    • 美國
    • 加拿大
  • 市場魅力分析

第10章 歐洲的小鼠模型技術市場分析與預測

第11章 亞太地區的小鼠模型技術市場分析與預測

第12章 南美的小鼠模型技術市場分析與預測

第13章 中東·非洲的小鼠模型技術市場分析與預測

第14章 競爭情形

  • 市場企業 - 競爭矩陣:階層·不同企業規模
  • 市場佔有率分析:各企業(2021年)
  • 企業簡介
    • BIOCYTOGEN
    • Charles River Laboratories
    • Cyagen Biosciences
    • Gempharmatech
    • genOway
    • ingenious targeting laboratory
    • Merck KGaA
    • Ozgene Pty Ltd.
    • Taconic Biosciences, Inc.
    • PolyGene AG
    • THE JACKSON LABORATORY
    • Yale School of Medicine
    • University of North Carolina
    • University of Nebraska Medical Center
    • Monash University
    • UMass Chan Medical School
    • University of Bonn
    • Columbia University
    • The University of Arizona
Product Code: TMRGL84893

The report provides revenue of the global mice model technologies market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global mice model technologies market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the mice model technologies market.

The report delves into the competitive landscape of the global mice model technologies market. Key players operating in the global mice model technologies market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global mice model technologies market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Mice Model Technologies Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Mice Model Technologies Market Analysis and Forecasts, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Global Genetically Engineered Mouse Model Overview
  • 5.2. Regulatory Scenario by Region/globally
  • 5.3. Technological Advancements
  • 5.4. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
  • 5.5. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

6. Global Mice Model Technologies Market Analysis and Forecasts, By Technology

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast By Technology, 2017-2031
    • 6.3.1. CRISPR Knockout
    • 6.3.2. CRISPR Knockin
    • 6.3.3. Random Insertions
    • 6.3.4. Large, Targeted Insertions
    • 6.3.5. ES Cell Modification (Homologous Recombination)
    • 6.3.6. Others
  • 6.4. Market Attractiveness By Technology

7. Global Mice Model Technologies Market Analysis and Forecasts, By End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast By End-user, 2017-2031
    • 7.3.1. Pharmaceutical Companies
    • 7.3.2. Biotechnology Companies
    • 7.3.3. Academic and Research Facilities
    • 7.3.4. Contract Research and Manufacturing Organizations
  • 7.4. Market Attractiveness By End-user

8. Global Mice Model Technologies Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast By Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness By Country/Region

9. North America Mice Model Technologies Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast By Technology, 2017-2031
    • 9.2.1. CRISPR Knockout
    • 9.2.2. CRISPR Knockin
    • 9.2.3. Random Insertions
    • 9.2.4. Large, Targeted Insertions
    • 9.2.5. ES Cell Modification (Homologous Recombination)
    • 9.2.6. Others
  • 9.3. Market Value Forecast By End-user, 2017-2031
    • 9.3.1. Pharmaceutical Companies
    • 9.3.2. Biotechnology Companies
    • 9.3.3. Academic and Research Facilities
    • 9.3.4. Contract Research and Manufacturing Organizations
  • 9.4. Market Value Forecast By End-user by Technology, 2017-2031
    • 9.4.1. Pharmaceutical Companies
      • 9.4.1.1. CRISPR Knockout
      • 9.4.1.2. CRISPR Knockin
      • 9.4.1.3. Random Insertions
      • 9.4.1.4. Large, Targeted Insertions
      • 9.4.1.5. ES Cell Modification (Homologous Recombination)
      • 9.4.1.6. Others
    • 9.4.2. Biotechnology Companies
      • 9.4.2.1. CRISPR Knockout
      • 9.4.2.2. CRISPR Knockin
      • 9.4.2.3. Random Insertions
      • 9.4.2.4. Large, Targeted Insertions
      • 9.4.2.5. ES Cell Modification (Homologous Recombination)
      • 9.4.2.6. Others
    • 9.4.3. Academic and Research Facilities
      • 9.4.3.1. CRISPR Knockout
      • 9.4.3.2. CRISPR Knockin
      • 9.4.3.3. Random Insertions
      • 9.4.3.4. Large, Targeted Insertions
      • 9.4.3.5. ES Cell Modification (Homologous Recombination)
      • 9.4.3.6. Others
    • 9.4.4. Contract Research and Manufacturing Organizations
      • 9.4.4.1. CRISPR Knockout
      • 9.4.4.2. CRISPR Knockin
      • 9.4.4.3. Random Insertions
      • 9.4.4.4. Large, Targeted Insertions
      • 9.4.4.5. ES Cell Modification (Homologous Recombination)
      • 9.4.4.6. Others
  • 9.5. Market Value Forecast By Country, 2017-2031
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Technology
    • 9.6.2. By End-user
    • 9.6.3. By End-user by Technology
    • 9.6.4. By Country

10. Europe Mice Model Technologies Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast By Technology, 2017-2031
    • 10.2.1. CRISPR Knockout
    • 10.2.2. CRISPR Knockin
    • 10.2.3. Random Insertions
    • 10.2.4. Large, Targeted Insertions
    • 10.2.5. ES Cell Modification (Homologous Recombination)
    • 10.2.6. Others
  • 10.3. Market Value Forecast By End-user, 2017-2031
    • 10.3.1. Pharmaceutical Companies
    • 10.3.2. Biotechnology Companies
    • 10.3.3. Academic and Research Facilities
    • 10.3.4. Contract Research and Manufacturing Organizations
  • 10.4. Market Value Forecast By End-user by Technology, 2017-2031
    • 10.4.1. Pharmaceutical Companies
      • 10.4.1.1. CRISPR Knockout
      • 10.4.1.2. CRISPR Knockin
      • 10.4.1.3. Random Insertions
      • 10.4.1.4. Large, Targeted Insertions
      • 10.4.1.5. ES Cell Modification (Homologous Recombination)
      • 10.4.1.6. Others
    • 10.4.2. Biotechnology Companies
      • 10.4.2.1. CRISPR Knockout
      • 10.4.2.2. CRISPR Knockin
      • 10.4.2.3. Random Insertions
      • 10.4.2.4. Large, Targeted Insertions
      • 10.4.2.5. ES Cell Modification (Homologous Recombination)
      • 10.4.2.6. Others
    • 10.4.3. Academic and Research Facilities
      • 10.4.3.1. CRISPR Knockout
      • 10.4.3.2. CRISPR Knockin
      • 10.4.3.3. Random Insertions
      • 10.4.3.4. Large, Targeted Insertions
      • 10.4.3.5. ES Cell Modification (Homologous Recombination)
      • 10.4.3.6. Others
    • 10.4.4. Contract Research and Manufacturing Organizations
      • 10.4.4.1. CRISPR Knockout
      • 10.4.4.2. CRISPR Knockin
      • 10.4.4.3. Random Insertions
      • 10.4.4.4. Large, Targeted Insertions
      • 10.4.4.5. ES Cell Modification (Homologous Recombination)
      • 10.4.4.6. Others
  • 10.5. Market Value Forecast By Country/Sub-Region, 2017-2031
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Technology
    • 10.6.2. By End-user
    • 10.6.3. By End-user by Technology
    • 10.6.4. By Country/Sub-Region

11. Asia Pacific Mice Model Technologies Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast By Technology, 2017-2031
    • 11.2.1. CRISPR Knockout
    • 11.2.2. CRISPR Knockin
    • 11.2.3. Random Insertions
    • 11.2.4. Large, Targeted Insertions
    • 11.2.5. ES Cell Modification (Homologous Recombination)
    • 11.2.6. Others
  • 11.3. Market Value Forecast By End-user, 2017-2031
    • 11.3.1. Pharmaceutical Companies
    • 11.3.2. Biotechnology Companies
    • 11.3.3. Academic and Research Facilities
    • 11.3.4. Contract Research and Manufacturing Organizations
  • 11.4. Market Value Forecast By End-user by Technology, 2017-2031
    • 11.4.1. Pharmaceutical Companies
      • 11.4.1.1. CRISPR Knockout
      • 11.4.1.2. CRISPR Knockin
      • 11.4.1.3. Random Insertions
      • 11.4.1.4. Large, Targeted Insertions
      • 11.4.1.5. ES Cell Modification (Homologous Recombination)
      • 11.4.1.6. Others
    • 11.4.2. Biotechnology Companies
      • 11.4.2.1. CRISPR Knockout
      • 11.4.2.2. CRISPR Knockin
      • 11.4.2.3. Random Insertions
      • 11.4.2.4. Large, Targeted Insertions
      • 11.4.2.5. ES Cell Modification (Homologous Recombination)
      • 11.4.2.6. Others
    • 11.4.3. Academic and Research Facilities
      • 11.4.3.1. CRISPR Knockout
      • 11.4.3.2. CRISPR Knockin
      • 11.4.3.3. Random Insertions
      • 11.4.3.4. Large, Targeted Insertions
      • 11.4.3.5. ES Cell Modification (Homologous Recombination)
      • 11.4.3.6. Others
    • 11.4.4. Contract Research and Manufacturing Organizations
      • 11.4.4.1. CRISPR Knockout
      • 11.4.4.2. CRISPR Knockin
      • 11.4.4.3. Random Insertions
      • 11.4.4.4. Large, Targeted Insertions
      • 11.4.4.5. ES Cell Modification (Homologous Recombination)
      • 11.4.4.6. Others
  • 11.5. Market Value Forecast By Country/Sub-Region, 2017-2031
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Technology
    • 11.6.2. By End-user
    • 11.6.3. By End-user by Technology
    • 11.6.4. By Country/Sub-Region

12. Latin America Mice Model Technologies Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast By Technology, 2017-2031
    • 12.2.1. CRISPR Knockout
    • 12.2.2. CRISPR Knockin
    • 12.2.3. Random Insertions
    • 12.2.4. Large, Targeted Insertions
    • 12.2.5. ES Cell Modification (Homologous Recombination)
    • 12.2.6. Others
  • 12.3. Market Value Forecast By End-user, 2017-2031
    • 12.3.1. Pharmaceutical Companies
    • 12.3.2. Biotechnology Companies
    • 12.3.3. Academic and Research Facilities
    • 12.3.4. Contract Research and Manufacturing Organizations
  • 12.4. Market Value Forecast By End-user by Technology, 2017-2031
    • 12.4.1. Pharmaceutical Companies
      • 12.4.1.1. CRISPR Knockout
      • 12.4.1.2. CRISPR Knockin
      • 12.4.1.3. Random Insertions
      • 12.4.1.4. Large, Targeted Insertions
      • 12.4.1.5. ES Cell Modification (Homologous Recombination)
      • 12.4.1.6. Others
    • 12.4.2. Biotechnology Companies
      • 12.4.2.1. CRISPR Knockout
      • 12.4.2.2. CRISPR Knockin
      • 12.4.2.3. Random Insertions
      • 12.4.2.4. Large, Targeted Insertions
      • 12.4.2.5. ES Cell Modification (Homologous Recombination)
      • 12.4.2.6. Others
    • 12.4.3. Academic and Research Facilities
      • 12.4.3.1. CRISPR Knockout
      • 12.4.3.2. CRISPR Knockin
      • 12.4.3.3. Random Insertions
      • 12.4.3.4. Large, Targeted Insertions
      • 12.4.3.5. ES Cell Modification (Homologous Recombination)
      • 12.4.3.6. Others
    • 12.4.4. Contract Research and Manufacturing Organizations
      • 12.4.4.1. CRISPR Knockout
      • 12.4.4.2. CRISPR Knockin
      • 12.4.4.3. Random Insertions
      • 12.4.4.4. Large, Targeted Insertions
      • 12.4.4.5. ES Cell Modification (Homologous Recombination)
      • 12.4.4.6. Others
  • 12.5. Market Value Forecast By Country/Sub-Region, 2017-2031
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Technology
    • 12.6.2. By End-user
    • 12.6.3. By End-user by Technology
    • 12.6.4. By Country/Sub-Region

13. Middle East & Africa Mice Model Technologies Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast By Technology, 2017-2031
    • 13.2.1. CRISPR Knockout
    • 13.2.2. CRISPR Knockin
    • 13.2.3. Random Insertions
    • 13.2.4. Large, Targeted Insertions
    • 13.2.5. ES Cell Modification (Homologous Recombination)
    • 13.2.6. Others
  • 13.3. Market Value Forecast By End-user, 2017-2031
    • 13.3.1. Pharmaceutical Companies
    • 13.3.2. Biotechnology Companies
    • 13.3.3. Academic and Research Facilities
    • 13.3.4. Contract Research and Manufacturing Organizations
  • 13.4. Market Value Forecast By End-user by Technology, 2017-2031
    • 13.4.1. Pharmaceutical Companies
      • 13.4.1.1. CRISPR Knockout
      • 13.4.1.2. CRISPR Knockin
      • 13.4.1.3. Random Insertions
      • 13.4.1.4. Large, Targeted Insertions
      • 13.4.1.5. ES Cell Modification (Homologous Recombination)
      • 13.4.1.6. Others
    • 13.4.2. Biotechnology Companies
      • 13.4.2.1. CRISPR Knockout
      • 13.4.2.2. CRISPR Knockin
      • 13.4.2.3. Random Insertions
      • 13.4.2.4. Large, Targeted Insertions
      • 13.4.2.5. ES Cell Modification (Homologous Recombination)
      • 13.4.2.6. Others
    • 13.4.3. Academic and Research Facilities
      • 13.4.3.1. CRISPR Knockout
      • 13.4.3.2. CRISPR Knockin
      • 13.4.3.3. Random Insertions
      • 13.4.3.4. Large, Targeted Insertions
      • 13.4.3.5. ES Cell Modification (Homologous Recombination)
      • 13.4.3.6. Others
    • 13.4.4. Contract Research and Manufacturing Organizations
      • 13.4.4.1. CRISPR Knockout
      • 13.4.4.2. CRISPR Knockin
      • 13.4.4.3. Random Insertions
      • 13.4.4.4. Large, Targeted Insertions
      • 13.4.4.5. ES Cell Modification (Homologous Recombination)
      • 13.4.4.6. Others
  • 13.5. Market Value Forecast By Country/Sub-Region, 2017-2031
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Technology
    • 13.6.2. By End-user
    • 13.6.3. By End-user by Technology
    • 13.6.4. By Country/Sub-Region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis By Company (2021)
    • 14.2.1. Global
    • 14.2.2. North America
    • 14.2.3. Europe
    • 14.2.4. By Asia-Pacific
    • 14.2.5. By Latin America
    • 14.2.6. By Middle East & Africa
  • 14.3. Company Profiles
    • 14.3.1. BIOCYTOGEN
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Strategic Overview
    • 14.3.2. Charles River Laboratories
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Strategic Overview
    • 14.3.3. Cyagen Biosciences
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Strategic Overview
    • 14.3.4. Gempharmatech
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Strategic Overview
    • 14.3.5. genOway
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Strategic Overview
    • 14.3.6. ingenious targeting laboratory
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Strategic Overview
    • 14.3.7. Merck KGaA
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Strategic Overview
    • 14.3.8. Ozgene Pty Ltd.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Strategic Overview
    • 14.3.9. Taconic Biosciences, Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Strategic Overview
    • 14.3.10. PolyGene AG
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Strategic Overview
    • 14.3.11. THE JACKSON LABORATORY
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Product Portfolio
      • 14.3.11.3. SWOT Analysis
      • 14.3.11.4. Strategic Overview
    • 14.3.12. Yale School of Medicine
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Product Portfolio
      • 14.3.12.3. SWOT Analysis
      • 14.3.12.4. Strategic Overview
    • 14.3.13. University of North Carolina
      • 14.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.13.2. Product Portfolio
      • 14.3.13.3. SWOT Analysis
      • 14.3.13.4. Strategic Overview
    • 14.3.14. University of Nebraska Medical Center
      • 14.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.14.2. Product Portfolio
      • 14.3.14.3. SWOT Analysis
      • 14.3.14.4. Strategic Overview
    • 14.3.15. Monash University
      • 14.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.15.2. Product Portfolio
      • 14.3.15.3. SWOT Analysis
      • 14.3.15.4. Strategic Overview
    • 14.3.16. UMass Chan Medical School
      • 14.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.16.2. Product Portfolio
      • 14.3.16.3. SWOT Analysis
      • 14.3.16.4. Strategic Overview
    • 14.3.17. University of Bonn
      • 14.3.17.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.17.2. Product Portfolio
      • 14.3.17.3. SWOT Analysis
      • 14.3.17.4. Strategic Overview
    • 14.3.18. Columbia University
      • 14.3.18.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.18.2. Product Portfolio
      • 14.3.18.3. SWOT Analysis
      • 14.3.18.4. Strategic Overview
    • 14.3.19. The University of Arizona
      • 14.3.19.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.19.2. Product Portfolio
      • 14.3.19.3. SWOT Analysis
      • 14.3.19.4. Strategic Overview

List of Tables

  • Table 01: Price/Cost Analysis of Mice Models, by Region
  • Table 02: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 03: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
  • Table 05: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
  • Table 06: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
  • Table 07: Global Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
  • Table 08: Global Mice Model Technologies Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 09: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 10: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 11: North America Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 12: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
  • Table 13: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
  • Table 14: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
  • Table 15: North America Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
  • Table 16: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017-2031
  • Table 17: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 18: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 19: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
  • Table 20: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
  • Table 21: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
  • Table 22: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
  • Table 23: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 24: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 25: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
  • Table 27: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
  • Table 28: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
  • Table 29: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
  • Table 30: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 31: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 32: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 33: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
  • Table 34: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
  • Table 35: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Academic & Research Facilities by Technology, 2017-2031
  • Table 36: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031
  • Table 37: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 38: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by Technology, 2017-2031
  • Table 39: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 40: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Pharmaceutical Companies by Technology, 2017-2031
  • Table 41: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Biotechnology Companies by Technology, 2017-2031
  • Table 42: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Academic and Research Facilities by Technology, 2017-2031
  • Table 43: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, Contract Research and Manufacturing Organizations by Technology, 2017-2031

List of Figures

  • Figure 01: Global Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Mice Model Technologies Market Value Share, by Technology, 2021
  • Figure 03: Mice Model Technologies Market Value Share, by End-user, 2021
  • Figure 04: Mice Model Technologies Market Value Share, by Region, 2021
  • Figure 05: Global Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 06: Global Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 07: Global Mice Model Technologies Market Value (US$ Mn), by CRISPR Knockout, 2017-2031
  • Figure 08: Global Mice Model Technologies Market Value (US$ Mn), by CRISPR Knockin Mice, 2017-2031
  • Figure 09: Global Mice Model Technologies Market Value (US$ Mn), by Random Insertions, 2017-2031
  • Figure 10: Global Mice Model Technologies Market Value (US$ Mn), by Large, Targeted Insertions, 2017-2031
  • Figure 11: Global Mice Model Technologies Market Value (US$ Mn), by ES Cell Modification (Homologous Recombination), 2017-2031
  • Figure 12: Global Mice Model Technologies Market Value (US$ Mn), by Others, 2017-2031
  • Figure 13: Global Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 14: Global Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 15: Global Mice Model Technologies Market Value (US$ Mn), by Pharmaceutical Companies, 2017-2031
  • Figure 16: Global Mice Model Technologies Market Value (US$ Mn), by Biotechnology Companies, 2017-2031
  • Figure 17: Global Mice Model Technologies Market Value (US$ Mn), by Academic and Research Facilities, 2017-2031
  • Figure 18: Global Mice Model Technologies Market Value (US$ Mn), by Contract Research and Manufacturing Organizations, 2017-2031
  • Figure 19: Global Mice Model Technologies Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 20: Global Mice Model Technologies Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 21: North America Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 22: North America Mice Model Technologies Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 23: North America Mice Model Technologies Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 24: North America Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 25: North America Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 26: North America Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 27: North America Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 28: Europe Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 29: Europe Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 30: Europe Mice Model Technologies Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 31: Europe Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 32: Europe Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 33: Europe Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 34: Europe Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 35: Asia Pacific Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 36: Asia Pacific Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 37: Asia Pacific Mice Model Technologies Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 38: Asia Pacific Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 39: Asia Pacific Mice Model Technologies Market Attractiveness Index, by Technology, 2022-2031
  • Figure 40: Asia Pacific Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 41: Asia Pacific Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 42: Latin America Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 43: Latin America Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 44: Latin America Mice Model Technologies Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 45: Latin America Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 46: Latin America Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 47: Latin America Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 48: Latin America Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 49: Middle East & Africa Mice Model Technologies Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 50: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031
  • Figure 51: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031
  • Figure 52: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by Technology, 2021 and 2031
  • Figure 53: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by Technology, 2022-2031
  • Figure 54: Middle East & Africa Mice Model Technologies Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 55: Middle East & Africa Mice Model Technologies Market Attractiveness Analysis, by End-user, 2022-2031